Hepion Pharmaceuticals, Inc. (CTRVP)
OID · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
Peers in Healthcare
Hepion Pharmaceuticals, Inc. has no peer companies in this window.
Recent press releases
Hepion Pharmaceuticals, Inc. has not issued a press release in this window.
SEC filings
All filings →Hepion Pharmaceuticals, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Hepion Pharmaceuticals, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Hepion Pharmaceuticals, Inc.
All people →No officers or directors have been indexed for Hepion Pharmaceuticals, Inc..